PCN8 COST-EFFECTIVENESS ANALYSIS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV GENERIC PAMIDRONATE FOR BONE METASTASES FROM BREAST CANCER IN PATIENTS RECEIVING ORAL HORMONAL THERAPY IN THE UK
Nov 1, 2004, 00:00
10.1016/S1098-3015(10)65742-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)65742-7/fulltext
Title :
PCN8 COST-EFFECTIVENESS ANALYSIS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV GENERIC PAMIDRONATE FOR BONE METASTASES FROM BREAST CANCER IN PATIENTS RECEIVING ORAL HORMONAL THERAPY IN THE UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65742-7&doi=10.1016/S1098-3015(10)65742-7
First page :
Section Title :
Open access? :
No
Section Order :
109